449 related articles for article (PubMed ID: 26245674)
1. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.
Saha SK; Gordan JD; Kleinstiver BP; Vu P; Najem MS; Yeo JC; Shi L; Kato Y; Levin RS; Webber JT; Damon LJ; Egan RK; Greninger P; McDermott U; Garnett MJ; Jenkins RL; Rieger-Christ KM; Sullivan TB; Hezel AF; Liss AS; Mizukami Y; Goyal L; Ferrone CR; Zhu AX; Joung JK; Shokat KM; Benes CH; Bardeesy N
Cancer Discov; 2016 Jul; 6(7):727-39. PubMed ID: 27231123
[TBL] [Abstract][Full Text] [Related]
3. Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma.
Wang T; Drill E; Vakiani E; Pak LM; Boerner T; Askan G; Schvartzman JM; Simpson AL; Jarnagin WR; Sigel CS
Hum Pathol; 2019 Sep; 91():19-25. PubMed ID: 31121195
[TBL] [Abstract][Full Text] [Related]
4. IDH mutations in liver cell plasticity and biliary cancer.
Saha SK; Parachoniak CA; Bardeesy N
Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
[TBL] [Abstract][Full Text] [Related]
5. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
[TBL] [Abstract][Full Text] [Related]
6. SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma.
Luk IS; Bridgwater CM; Yu A; Boila LD; Yáñez-Bartolomé M; Lampano AE; Hulahan TS; Boukhali M; Kathiresan M; Macarulla T; Kenerson HL; Yamamoto N; Sokolov D; Engstrom IA; Sullivan LB; Lampe PD; Cooper JA; Yeung RS; Tian TV; Haas W; Saha SK; Kugel S
Sci Transl Med; 2024 May; 16(747):eadj7685. PubMed ID: 38748774
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
8. Predicting IDH mutation status of intrahepatic cholangiocarcinomas based on contrast-enhanced CT features.
Zhu Y; Chen J; Kong W; Mao L; Kong W; Zhou Q; Zhou Z; Zhu B; Wang Z; He J; Qiu Y
Eur Radiol; 2018 Jan; 28(1):159-169. PubMed ID: 28752218
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
[TBL] [Abstract][Full Text] [Related]
11. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract][Full Text] [Related]
12. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Immunogenomic Profiling of
Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
[TBL] [Abstract][Full Text] [Related]
15. IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
[TBL] [Abstract][Full Text] [Related]
16. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Borger DR; Zhu AX
Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
[No Abstract] [Full Text] [Related]
17. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.
Saha SK; Parachoniak CA; Ghanta KS; Fitamant J; Ross KN; Najem MS; Gurumurthy S; Akbay EA; Sia D; Cornella H; Miltiadous O; Walesky C; Deshpande V; Zhu AX; Hezel AF; Yen KE; Straley KS; Travins J; Popovici-Muller J; Gliser C; Ferrone CR; Apte U; Llovet JM; Wong KK; Ramaswamy S; Bardeesy N
Nature; 2014 Sep; 513(7516):110-4. PubMed ID: 25043045
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With
Lapin M; Huang HJ; Chagani S; Javle M; Shroff RT; Pant S; Gouda MA; Raina A; Madwani K; Holley VR; Call SG; Dustin DJ; Lanman RB; Meric-Bernstam F; Raymond VM; Kwong LN; Janku F
JCO Precis Oncol; 2022 Feb; 6():e2100197. PubMed ID: 35171660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
